Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Endometrial Neoplasms × sintilimab × Clear all

Phase

Phase NA 1 Phase 3 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 4 Stomach Neoplasms 2 Small Cell Lung Carcinoma 1 Neoplasms 1 Liver Neoplasms 1 Hepatoblastoma 1 Endometrial Neoplasms 1 Advanced Solid Tumor 1

Interventions

Paclitaxel 3 Megestrol Acetate 3 Carboplatin 3 Medroxyprogesterone Acetate 2 Cisplatin 2 spartalizumab 1 sintilimab 1 olaparib 1 niraparib 1 navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1 durvalumab 1 Tablets 1 Progestins 1 Observation 1 Letrozole 1 Gonadotropin-Releasing Hormone 1 Drug Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07319429 2026-03-13

FEMUS

Fudan University

Phase 2/3 Recruiting

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡